Aktis Oncology, Inc. (AKTS) Stock Overview
NASDAQ · Healthcare · Biotechnology
✓ Sourced directly from Yahoo Finance · Checked for accuracy at every rebuild · Snapshot: 6 September 2026
About Aktis Oncology, Inc.
Aktis Oncology, Inc., a clinical-stage oncology company, engages in the research, development, and commercialization of targeted radiopharmaceuticals to treat various solid tumor cancers. The company's lead product candidate includes [225Ac]Ac-AKY-1189, a miniprotein radioconjugate platform…
Source: Yahoo Finance
Sector & Industry
Aktis Oncology, Inc. operates in the Healthcare sector, within the Biotechnology industry group. It is listed on the NASDAQ exchange.
Aktis Oncology, Inc. at a Glance
| Company | Aktis Oncology, Inc. |
| Ticker | AKTS |
| Exchange | NASDAQ |
| Currency | USD |
| Price | $27.05 |
| Market cap | $1.50B |
| P/E ratio (trailing) | — |
| EPS (trailing) | -$1.32 |
| 52-week high | $34.19 |
| 52-week low | $14.72 |
| Dividend yield | — |
| Ex-dividend date | — |
| Beta | — |
| Return on equity (ROE) | — |
| Debt-to-equity | 2.32% |
| Average volume | 388,469 |
| Shares outstanding | 53.75M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 79 |
| Country | United States |
Investing Essentials
As an Amazon Associate we earn from qualifying purchases. Links below are affiliate links.
Evaluating pharma pipelines, devices and healthcare economics.
Check Price →Benjamin Graham's classic on value investing — the book Warren Buffett calls the best ever written on the subject.
Check Price →Peter Lynch on how everyday investors can spot winners before the professionals do.
Check Price →Frequently Asked Questions
- What is Aktis Oncology, Inc.'s current P/E ratio?
- Aktis Oncology, Inc. (AKTS) has a trailing P/E ratio of — as of our 6 September 2026 data snapshot. Learn what the P/E ratio means →
- What is Aktis Oncology, Inc.'s market capitalisation?
- Aktis Oncology, Inc.'s market cap is $1.50B based on our latest snapshot. See how it ranks by market cap →
- What is AKTS's 52-week range?
- Over the past 52 weeks, AKTS has traded between $14.72 and $34.19. What does the 52-week range mean? →
- How volatile is Aktis Oncology, Inc. compared to the market?
- Aktis Oncology, Inc. has a beta of —. What does beta measure? →
- Does Aktis Oncology, Inc. pay a dividend?
- Aktis Oncology, Inc. does not currently pay a dividend according to our latest data.
- What exchange is AKTS listed on?
- AKTS is listed on the NASDAQ. Browse all NASDAQ-listed stocks →
- What sector is Aktis Oncology, Inc. in?
- Aktis Oncology, Inc. is classified in the Healthcare sector. Compare with Healthcare peers →
Prefer raw numbers at a glance? Browse our size and reference charts for quick lookups.
Many readers keep a stock investing journal to log positions and theses alongside pages like this one, and a dedicated financial calculator to hand for quick valuation maths.
Recommended Reading & Tools
Philip Fisher on what makes a business worth owning for the long term.
Check Price →Burton Malkiel's evidence-based guide to markets, indexing and long-term strategy.
Check Price →Morgan Housel's short lessons on behaviour, luck and long-term wealth.
Check Price →